| Hazard Information | Back Directory | [Uses]
ATR-IN-23 (Compound 34) is a potent and selective ATR inhibitor with an IC50 of 1.5 nM. ATR-IN-23 has potent antiproliferative effects on LoVo cells and synthetic lethality on HT-29 cells, and can be used in the study of DNA damage response (DDR)-deficient cancers[1]. | [in vivo]
ATR-IN-23 shows acute toxicity at a maximum concentration of 2000 mg/kg and possesses moderate safety in ICR mice[1].
ATR-IN-23 (50 mg/kg; once a day or twice a day; p.o.; 21 days) exhibits moderate antitumor efficacy in BALB/c nude mice[1]. | Animal Model: | BALB/c nude mice[1] | | Dosage: | 50 mg/kg | | Administration: | p.o., once a day or twice a day for 21 consecutive days, dissolved in a solution of DMSO (10%), solutol (10%), and saline (80%) | | Result: | Exhibited moderate antitumor efficacy, with a tumor growth inhibition (TGI) value of 55% at dosages of 50 mg/kg twice a day. |
| [References]
[1] Duan Y, et al. Discovery of Thieno[3,2-d]pyrimidine derivatives as potent and selective inhibitors of ataxia telangiectasia mutated and Rad3 related (ATR) kinase. Eur J Med Chem. 2023 Jul 5;255:115370. DOI:10.1016/j.ejmech.2023.115370 |
|
|